Medical Equipment

Pharmacogenomics Market Outlook 2025–2029: Emerging Opportunities and Key Drivers

December 4, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pharmacogenomics market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present Size Of The Pharmacogenomics Market And What Value Is Projected For 2029?

The pharmacogenomics market size has seen substantial expansion in recent years. It is anticipated to increase from $8.94 billion in 2024 to $9.84 billion in 2025, with a compound annual growth rate (CAGR) of 10.0%. The growth observed historically can be credited to strong economic development in emerging markets, a rising emphasis on personalized medicine, the improvement of advanced healthcare infrastructure, and elevated healthcare expenditure.

The pharmacogenomics market is projected to experience substantial expansion over the coming years. This market is set to reach $14.53 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 10.2%. This anticipated growth during the forecast period is primarily driven by factors such as the expanding aging demographic, the rising prevalence of chronic illnesses, overall population increase, and the growing need for effective cancer therapies. Key trends anticipated during this period encompass the launch of genome editing solutions for more in-depth analysis of advanced therapies, an emphasis on incorporating artificial intelligence (AI) into genomics for genetic data analysis, growing advancements in metagenomics, strategic alliances and joint ventures among industry participants, the introduction of three-dimensional (3D) genomics to investigate impacts on gene expression and function, novel product developments targeting infectious diseases and gene editing, and the creation of psychotropic pharmacogenomics tests to facilitate more informed medical choices.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp

What Factors Are Boosting The Pharmacogenomics Market?

The expanding requirement for precision medicine is propelling the demand for the pharmacogenomics market. This medical approach proposes customized healthcare, where medical decisions, treatments, practices, or products are specifically tailored to a subset of patients, moving away from a universal “one-drug-fits-all” model. The rising interest in precision medicine stems from its advanced state in oncology, alongside its broader, exciting applications extending beyond cancer into late-stage conditions such as rare and genetic diseases. The primary objective of precision medicine involves integrating genetic and environmental information about specific diseases and/or their responses to particular treatments. For instance, according to an article published on Linchpinseo in March 2022, the increasing investment in precision medicine from leading pharmaceutical companies is anticipated to experience a 1/3 increase in the next five years. Furthermore, in the USA, 30 million people with type 2 diabetes are diagnosed and treated, and precision medicine offers individualized treatment that will re-calibrate current practices. Therefore, the growing demand for precision medicine will continue to drive the pharmacogenomics market.

What Are The Core Segmentation Criteria In The Pharmacogenomics Market?

The pharmacogenomicsmarket covered in this report is segmented –

1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies

2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications

3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users

Subsegments:

1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing

2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR

3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis

4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)

5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays

6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools

Which Emerging Trends Are Reshaping The Pharmacogenomics Market Landscape?

A significant trend gaining popularity in the pharmacogenomics market is technological advancement. Medicine manufacturers are concentrating on various approaches to pharmacogenomics analysis to provide cost-effective solutions for screening known polymorphisms and discovering novel variants. For instance, in May 2022, Invitae, a US-based medical laboratory organization, launched its expanded Pharmacogenomics Panel. The Invitae Pharmacogenomics (PGx) Panel, including the Mental Health Panel, offers insights into genetic responses to medications across diverse specialties like primary care, cardiology, and oncology. With nearly 25% of patients experiencing atypical drug responses due to genetics, PGx testing is set to become a standard practice. Effective integration into healthcare demands enhanced support for providers to understand and apply PGx testing in their clinical environments.

Which Players Are Shaping The Competitive Landscape Of The PharmacogenomicsXX Market?

Major companies operating in the pharmacogenomics market include Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Xcelris Labs, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, Bayer AG, GlaxoSmithKline plc (GSK), F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas (CGBS), Dasa Group, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Laboratório Richet, Laboratório Exame, Genomika Diagnósticos

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

What Regional Trends Are Shaping Growth In The Pharmacogenomics Market?

North America was the largest region in the pharmacogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=7072&type=smp

Browse Through More Reports Similar to the Global Pharmacogenomics Market 2025, By The Business Research Company

Point Of Care Molecular Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/point-of-care-molecular-diagnostics-global-market-report

Molecular Diagnostics Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-devices-and-equipment-global-market-report

Molecular Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795